In fact, the therapeutic scenario of early-stage HER2+ breast tumors is in constant evolution, with pertuzumab having been approved for the neoadjuvant setting in combination with trastuzumab, and also in the adjuvant setting, for selected high-risk patients.44, 45, 46, 47 Similarly, adjuvant T-DM1 has been approved for patients treated with neoadjuvant anti-HER2-based regimens that do not achieve a pathologic complete response.30 The gene discussed is ERBB2; the disease is breast neoplasm.